Synageva BioPharma Files for Orphan Drug Designation for SBC-102, Being Developed to be the First Enzyme Replacement Therapy to Treat Lysosomal Acid Lipase Deficiency - A Progressive, Often Fatal Disease
Synageva BioPharma Announces Completion of $45 Million Financing With New $12 Million Investment, Addition of New Leaf Venture Partners to Investor Group, and Expansion of Senior Leadership Team